4,273 Shares in Laboratory Co. of America Holdings (NYSE:LH) Acquired by Alexander Randolph Advisory Inc.

Alexander Randolph Advisory Inc. acquired a new stake in Laboratory Co. of America Holdings (NYSE:LH) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 4,273 shares of the medical research company’s stock, valued at approximately $955,000. Laboratory Co. of America comprises approximately 0.8% of Alexander Randolph Advisory Inc.’s investment portfolio, making the stock its 29th largest position.

Other institutional investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its holdings in Laboratory Co. of America by 2.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 114,488 shares of the medical research company’s stock valued at $25,012,000 after purchasing an additional 2,934 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Laboratory Co. of America by 17.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 101,019 shares of the medical research company’s stock valued at $22,069,000 after acquiring an additional 14,708 shares in the last quarter. Great Valley Advisor Group Inc. purchased a new stake in shares of Laboratory Co. of America during the second quarter worth about $473,000. CANADA LIFE ASSURANCE Co lifted its stake in shares of Laboratory Co. of America by 18.9% in the first quarter. CANADA LIFE ASSURANCE Co now owns 150,046 shares of the medical research company’s stock worth $32,802,000 after acquiring an additional 23,860 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in Laboratory Co. of America by 9.5% in the first quarter. Sei Investments Co. now owns 131,756 shares of the medical research company’s stock valued at $28,784,000 after purchasing an additional 11,441 shares during the last quarter. 95.94% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Laboratory Co. of America news, CFO Glenn A. Eisenberg sold 15,000 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $223.99, for a total transaction of $3,359,850.00. Following the transaction, the chief financial officer now owns 31,289 shares of the company’s stock, valued at approximately $7,008,423.11. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Glenn A. Eisenberg sold 15,000 shares of Laboratory Co. of America stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $223.99, for a total transaction of $3,359,850.00. Following the transaction, the chief financial officer now directly owns 31,289 shares in the company, valued at approximately $7,008,423.11. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Adam H. Schechter sold 6,189 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $243.47, for a total value of $1,506,835.83. Following the completion of the sale, the chief executive officer now owns 87,441 shares of the company’s stock, valued at approximately $21,289,260.27. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,189 shares of company stock valued at $5,550,786 over the last 90 days. 0.85% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

LH has been the topic of several recent analyst reports. Evercore ISI cut their price target on shares of Laboratory Co. of America from $250.00 to $240.00 and set an “in-line” rating on the stock in a report on Tuesday, September 24th. Hsbc Global Res upgraded shares of Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 30th. Bank of America lifted their price target on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Jefferies Financial Group upped their price objective on Laboratory Co. of America from $245.00 to $265.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, Robert W. Baird lifted their target price on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Laboratory Co. of America presently has an average rating of “Moderate Buy” and an average target price of $255.92.

Laboratory Co. of America Stock Performance

NYSE:LH traded up $1.28 during mid-day trading on Wednesday, hitting $245.54. The stock had a trading volume of 121,796 shares, compared to its average volume of 664,670. Laboratory Co. of America Holdings has a 52 week low of $191.97 and a 52 week high of $247.99. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $20.54 billion, a price-to-earnings ratio of 47.25, a P/E/G ratio of 2.01 and a beta of 1.05. The company has a 50 day simple moving average of $223.60 and a 200-day simple moving average of $215.03.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.02. Laboratory Co. of America had a return on equity of 15.27% and a net margin of 3.43%. The business had revenue of $3.28 billion during the quarter, compared to the consensus estimate of $3.26 billion. During the same period in the previous year, the firm posted $3.38 earnings per share. The business’s revenue was up 7.4% on a year-over-year basis. On average, research analysts expect that Laboratory Co. of America Holdings will post 14.53 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Tuesday, November 26th. Laboratory Co. of America’s dividend payout ratio is currently 55.71%.

About Laboratory Co. of America

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.